Tailoring cancer pill dosing for older adults with breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- You have advanced breast cancer that is hormone receptor-positive (HR+) and HER2-negative, and it cannot be cured with standard treatments.
- You have not received any systemic therapy (like chemotherapy or hormone therapy) for advanced breast cancer, though you may have taken hormone therapy for up to 28 days before starting this trial.
- If you have had breast cancer treatment before (like surgery or hormone therapy) and it came back more than 12 months after finishing a CDK 4/6 inhibitor, you may still qualify.
- You are able to swallow capsules and have adequate organ function.
- You do not have rapidly progressing disease (visceral crisis) or a history of other cancers in the past 3 years (except certain minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well different doses of CDK4/6 inhibitors (palbociclib or ribociclib) work in people aged 65 or older with HR+/HER2- metastatic breast cancer. It aims to find the best starting dose to balance effectiveness and side effects.
This study tests whether starting with a lower dose of chemotherapy works as well as the standard dose for people aged 70 and older with metastatic colorectal cancer. The goal is to find a treatment that is effective but gentler, with fewer side effects.
This study looks at how well older breast cancer patients (70 years and older) do when treated with a type of drug called a CDK4/6 inhibitor along with hormone therapy after surgery. The goal is to use simple health checks to help doctors decide if this treatment is right for you.
This study looks at how well CDK4/6 inhibitors work in older adults with breast cancer who are taking these drugs after surgery to help prevent the cancer from coming back. It will follow patients over time to learn more about their experiences.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This study tests a combination of three drugs—trastuzumab and pertuzumab (which target HER2 protein on cancer cells) plus a low-dose chemotherapy called vinorelbine—given before surgery in people aged 70 and older with HER2-positive breast cancer. The goal is to shrink the tumor so surgery is more effective while being gentler on older patients.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.